Novel Therapeutic Targets in Liver Fibrosis
Liver fibrosis is end-stage liver disease that can be rescued. If irritation continues due to viral infection, schistosomiasis and alcoholism, liver fibrosis can progress to liver cirrhosis and even cancer. The US Food and Drug Administration has not approved any drugs that act directly against live...
Guardado en:
Autores principales: | Jinhang Zhang, Qinhui Liu, Jinhan He, Yanping Li |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/58f517150ba14c2e9fbd90e1f5c13c15 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Non-invasive Diagnostics of Liver Fibrosis
por: Mihaylov R., et al.
Publicado: (2017) -
MitoQ inhibits hepatic stellate cell activation and liver fibrosis by enhancing PINK1/parkin-mediated mitophagy
por: Dou Shi-Ying, et al.
Publicado: (2021) -
Foresight regarding drug candidates acting on the succinate–GPR91 signalling pathway for non-alcoholic steatohepatitis (NASH) treatment
por: Chengyuan Liang, et al.
Publicado: (2021) -
Association of Cholecystectomy With Liver Fibrosis and Cirrhosis Among Adults in the USA: A Population-Based Propensity Score-Matched Study
por: Zhi-Qin Xie, et al.
Publicado: (2021) -
Editorial: Organ Fibrosis: Pathogenesis, Biomarkers and Therapeutic Targets
por: Henricus A. M. Mutsaers, et al.
Publicado: (2021)